Pharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administration

Basit Öğe Kaydı
dc.authoridCoskun, Devran/0000-0003-1151-1861
dc.contributor.authorCoskun, Devran
dc.contributor.authorCorum, Orhan
dc.contributor.authorCorum, Duygu Durna
dc.contributor.authorUney, Kamil
dc.date.accessioned2024-09-18T20:04:26Z
dc.date.available2024-09-18T20:04:26Z
dc.date.issued2023
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective To determine the pharmacokinetics and bioavailability of meloxicam following intravenous (IV), intramuscular (IM), and oral administrations at a dose of 1.0 mg kg(-1) in Pekin ducks.Study design Randomized experimental trial.Animals A total of 18 clinically healthy male Pekin ducks.Methods Pekin ducks were randomly assigned to three groups of six ducks: IV, IM and oral. Meloxicam (1.0 mg kg(-1)) was administered to each Pekin duck. A non-compartmental analysis was used to evaluate pharmacokinetic parameters.Results No local or systemic adverse effects were observed in any bird. Meloxicam was detected in the plasma up to 120 hours following IV, IM or oral administration. The elimination half-life of the IV route was slightly shorter than that of the IM and oral routes (p < 0.05). Following IV administration, volume of distribution at steady state and total clearance were 133.17 mL kg(-1) and 6.68 mL kg(-1) hour(-1), respectively. The mean absorption time was 2.29 hours for IM and 1.13 hours for oral route. There were significant differences between IM and oral administration for the peak plasma concentration (C-max), time to reach C-max and bioavailability (p < 0.05).Conclusions and clinical relevance Meloxicam showed long elimination half-life and high bioavailability following IM and oral administration. Meloxicam in Pekin ducks provided the effective therapeutic concentration indicated in other species for up to 48 hours. However, there is a need to determine the clinical efficacy of meloxicam in Pekin ducks.en_US
dc.identifier.doi10.1016/j.vaa.2023.07.007
dc.identifier.endpage484en_US
dc.identifier.issn1467-2987
dc.identifier.issn1467-2995
dc.identifier.issue6en_US
dc.identifier.pmid37620232en_US
dc.identifier.startpage477en_US
dc.identifier.urihttps://doi.org/10.1016/j.vaa.2023.07.007
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8165
dc.identifier.volume50en_US
dc.identifier.wosWOS:001110200200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofVeterinary Anaesthesia and Analgesiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbioavailabilityen_US
dc.subjectducken_US
dc.subjectmeloxicamen_US
dc.subjectpharmacokineticsen_US
dc.titlePharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administrationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu